Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

NCT03567291 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
228
Enrollment
INDUSTRY
Sponsor class

Stopped The parent trials did not meet the primary endpoints of reduction in motor and phonic tics.

Conditions

Interventions

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Collaborators